144 related articles for article (PubMed ID: 7607905)
21. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
Lejeune FJ; Eggermont AM
J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
[No Abstract] [Full Text] [Related]
22. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs].
Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM
Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515
[TBL] [Abstract][Full Text] [Related]
23. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
[TBL] [Abstract][Full Text] [Related]
24. [Value of isolation-perfusion of the limbs in melanomas and sarcomas].
Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B
Ann Chir; 1995; 49(1):9-12. PubMed ID: 7741477
[No Abstract] [Full Text] [Related]
25. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan.
Hohenberger P; Bida B; Schlag PM
Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039
[No Abstract] [Full Text] [Related]
26. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J
Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162
[TBL] [Abstract][Full Text] [Related]
27. Malignant melanoma and isolated limb perfusion.
Giraud RM
S Afr J Surg; 1984; 22(4):243-8. PubMed ID: 6523302
[No Abstract] [Full Text] [Related]
28. Isolated limb perfusion for malignant melanoma.
Alexander HR; Fraker DL; Bartlett DL
Semin Surg Oncol; 1996; 12(6):416-28. PubMed ID: 8914206
[TBL] [Abstract][Full Text] [Related]
29. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM
Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309
[TBL] [Abstract][Full Text] [Related]
30. [Isolated extremity perfusion with TNF-alpha and melphalan in unresectable soft tissue sarcoma. Indications, principles and technique].
Taeger G; Ruchholtz S; Niebel W; Müller S; Nast-Kolb D
Unfallchirurg; 2004 Jul; 107(7):619-23. PubMed ID: 15252711
[No Abstract] [Full Text] [Related]
31. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha.
Renard N; Nooijen PT; Schalkwijk L; De Waal RM; Eggermont AM; Liénard D; Kroon BB; Lejeune FJ; Ruiter DJ
J Pathol; 1995 Jul; 176(3):279-87. PubMed ID: 7674090
[TBL] [Abstract][Full Text] [Related]
32. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion.
Liénard D; Lejeune FJ; Ewalenko P
World J Surg; 1992; 16(2):234-40. PubMed ID: 1561804
[TBL] [Abstract][Full Text] [Related]
33. Isolated limb perfusion for malignant melanoma.
Rosin RD; Westbury G
Practitioner; 1980 Oct; 224(1348):1031-6. PubMed ID: 7220430
[No Abstract] [Full Text] [Related]
34. Isolated limb perfusion for melanoma.
Kroon BB; Noorda EM; Vrouenraets BC; Nieweg OE
J Surg Oncol; 2002 Apr; 79(4):252-5. PubMed ID: 11920783
[No Abstract] [Full Text] [Related]
35. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results.
Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
J Infus Chemother; 1995; 5(2):73-81. PubMed ID: 8521239
[TBL] [Abstract][Full Text] [Related]
36. Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom.
Hill S; Thomas JM
Melanoma Res; 1994 Mar; 4 Suppl 1():31-4. PubMed ID: 8038593
[TBL] [Abstract][Full Text] [Related]
37. Treatment of melanoma in-transit metastases confined to the limb.
Eggermont AM
Cancer Surv; 1996; 26():335-49. PubMed ID: 8783582
[No Abstract] [Full Text] [Related]
38. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.
Liénard D; Eggermont AM; Schraffordt Koops H; Kroon BB; Rosenkaimer F; Autier P; Lejeune FJ
Melanoma Res; 1994 Mar; 4 Suppl 1():21-6. PubMed ID: 8038591
[TBL] [Abstract][Full Text] [Related]
39. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan.
Lejeune FJ; Deloof T; Ewalenko P; Fruhling J; Jabri M; Mathieu M; Nogaret JM; Verhest A
Recent Results Cancer Res; 1983; 86():268-76. PubMed ID: 6648008
[No Abstract] [Full Text] [Related]
40. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]